Moderna Secures $472M BARDA Contract Modification for COVID-19 Vaccine Dev’t

Moderna Secures $472M BARDA Contract Modification for COVID-19 Vaccine Dev’t
vaccine

Moderna has been awarded a potential $472M contract modification by the Biomedical Advanced Research and Development Authority to expand late-stage clinical trials of a messenger RNA-based vaccine candidate for the novel coronavirus.

BARDA’s additional funding commitment increases the potential value of the initial contract to $955M, the company said Sunday.

Under the modification, BARDA pledged funds to support Phase 3 tests of Moderna’s mRNA-1273 vaccine  including a study to be conducted with 30K participants.

The biotechnology firm will perform the participant-based trials with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases’ COVID-19 Prevention Trials Network.

“Encouraged by the Phase 1 data, we believe that our mRNA vaccine may aid in addressing the COVID-19 pandemic and preventing future outbreaks,” said Moderna CEO Stephane Bancel.

The company aims to deliver 500M to 1B doses of the potential COVID-19 vaccine starting next year as part of the Trump administration’s Operation Warp Speed.

Check Also

Norm Tew VP and GM Boeing

Boeing Submits Bid for Next-Generation Interceptor Program; Norm Tew Quoted

Boeing (NYSE: BA) has submitted its proposal for the Missile Defense Agency’s Next-Generation Interceptor program and offered a design that builds on the company's six decades of experience in weapons systems and strategic missile development.

AI

Deloitte to Help DoD Create AI Dev’t Environment Under $106M Task Order

Deloitte Consulting has received a potential four-year, $106.4M task order to provide a development environment for the Department of Defense's Joint Artificial Intelligence Center to test, validate and implement AI-based tools.